Market Cap 291.49M
Revenue (ttm) 0.00
Net Income (ttm) -55.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 574,100
Avg Vol 790,450
Day's Range N/A - N/A
Shares Out 54.90M
Stochastic %K 23%
Beta -0.94
Analysts Strong Sell
Price Target $20.17

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 3:49 PM
Enter: $CADL Calls Strike Price: $6 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.45 Sell Price: $0.81 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 1:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CADL Current Share Price: $5.40 Contracts: $CADL April 17, 2026 $6 Calls Scale in: $1.29- $1.58 Scale out: $2.01-$2.59 Can Easily Capture: 60% ROI Blended DTE: 174 Days | Join Elites here: https://liquidtheta.com
0 · Reply
deporte1800
deporte1800 Oct. 25 at 12:13 PM
$CADL I am looking forward to the presentation of the continuous BLA before July 1, a key date when many events we are all waiting for will be announced and Candel's capitalization will be well above 550 million.
1 · Reply
ActionCuresFear
ActionCuresFear Oct. 25 at 10:05 AM
$CADL wow, took me an hour of exploring my own posts and scrolling down on the CADL feed. Finally I think I found what you are looking for: https://stocktwits.com/ActionCuresFear/message/618636327 The direct link is in the thread
2 · Reply
Piero606
Piero606 Oct. 25 at 9:23 AM
$CADL but does the FDA care about the health of US patients who have prostate cancer? I also wonder why Candel and EMA are waiting for Fda to treat patients in Europe and around the world.
2 · Reply
PaulNipkow
PaulNipkow Oct. 25 at 7:20 AM
$CADL I remember an interview some weeks / months ago in which the CEO explained why the BLA is scheduled for Autumn 2026 - has anyone a link available ?
0 · Reply
Piero606
Piero606 Oct. 25 at 5:47 AM
$CADL The latter often fail precisely because of the lack of "diaphony" (cross-talk) between stromal and immune compartments - your ~80% of failures is in line with the literature. A systemic approach like this could reduce redundancy and maximize effectiveness, while also reducing off-target effects. • Clinical implications: If the complete data at SITC 2025 (November 5-9) confirm the effectiveness, it could open to combinations with ICI or CAR-T, especially in "cold" tumors such as pancreas or ovary. And the transformative potential for 70% of non-responders? It is optimistic but plausible, given the preclinical trials on oncological viruses that induce TLS-like structures.
0 · Reply
Piero606
Piero606 Oct. 25 at 5:47 AM
$CADL Recent studies confirm that the presence of mature TLS correlates with better survival in solid tumors (e.g. melanoma, NSCLC, lung), and their assembly is a "bottleneck" for antitumor immunity. Positioning the TLS inductor as a "TME reprogrammer" is right: it transforms a hostile environment into a pro-inflammatory one, potentially saving that 70% of patients who do not respond to ICI. • Multimodal innovation with HSV-1 oncolytic virus: Using a programmable HSV-1 is brilliant, because it exploits the selective lysis of cancer cells to release antigens and stimulate innate immunity (via PAMPs and DAMPs). The AI touch with enLIGHTEN™ to design multi-gene payloads that recapitulate the 4-phase cascade (probably: initial recruitment, stromal organization, DC/T trigger, B/HEV maturation) exceeds the limits of single agonists such as LIGHT or LTBR.
1 · Reply
strategicmind
strategicmind Oct. 24 at 11:56 PM
$CADL let’s go! Our fearless leader
1 · Reply
ShadowBull3745
ShadowBull3745 Oct. 24 at 10:31 PM
0 · Reply
Latest News on CADL
Candel Therapeutics to Present at Upcoming Investor Conferences

May 6, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences


Candel Therapeutics: Entering Its Pivotal Year

Feb 20, 2025, 10:45 AM EST - 8 months ago

Candel Therapeutics: Entering Its Pivotal Year


Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 10 months ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR


Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 11:00 PM EST - 11 months ago

Candel Therapeutics Announces Pricing of Public Offering


Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 12, 2024, 4:51 PM EST - 11 months ago

Candel Therapeutics Announces $80 Million Proposed Public Offering


Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 9:19 AM EST - 11 months ago

Candel Therapeutics Stock Surges Over 100% - Here's Why


Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:09 AM EST - 11 months ago

Candel Therapeutics' cancer drug meets late-stage trial goals


3 Biotech Names With Potential Catalysts By Year End

Jul 29, 2024, 3:32 PM EDT - 1 year ago

3 Biotech Names With Potential Catalysts By Year End

RCKT VRDN


Candel Therapeutics to Join Russell 3000® Index

Jun 11, 2024, 8:00 AM EDT - 1 year ago

Candel Therapeutics to Join Russell 3000® Index


MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 3:49 PM
Enter: $CADL Calls Strike Price: $6 Expiry Date: NOV 21 2025 Buy in Price: $0.45 - $0.45 Sell Price: $0.81 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 1:47 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CADL Current Share Price: $5.40 Contracts: $CADL April 17, 2026 $6 Calls Scale in: $1.29- $1.58 Scale out: $2.01-$2.59 Can Easily Capture: 60% ROI Blended DTE: 174 Days | Join Elites here: https://liquidtheta.com
0 · Reply
deporte1800
deporte1800 Oct. 25 at 12:13 PM
$CADL I am looking forward to the presentation of the continuous BLA before July 1, a key date when many events we are all waiting for will be announced and Candel's capitalization will be well above 550 million.
1 · Reply
ActionCuresFear
ActionCuresFear Oct. 25 at 10:05 AM
$CADL wow, took me an hour of exploring my own posts and scrolling down on the CADL feed. Finally I think I found what you are looking for: https://stocktwits.com/ActionCuresFear/message/618636327 The direct link is in the thread
2 · Reply
Piero606
Piero606 Oct. 25 at 9:23 AM
$CADL but does the FDA care about the health of US patients who have prostate cancer? I also wonder why Candel and EMA are waiting for Fda to treat patients in Europe and around the world.
2 · Reply
PaulNipkow
PaulNipkow Oct. 25 at 7:20 AM
$CADL I remember an interview some weeks / months ago in which the CEO explained why the BLA is scheduled for Autumn 2026 - has anyone a link available ?
0 · Reply
Piero606
Piero606 Oct. 25 at 5:47 AM
$CADL The latter often fail precisely because of the lack of "diaphony" (cross-talk) between stromal and immune compartments - your ~80% of failures is in line with the literature. A systemic approach like this could reduce redundancy and maximize effectiveness, while also reducing off-target effects. • Clinical implications: If the complete data at SITC 2025 (November 5-9) confirm the effectiveness, it could open to combinations with ICI or CAR-T, especially in "cold" tumors such as pancreas or ovary. And the transformative potential for 70% of non-responders? It is optimistic but plausible, given the preclinical trials on oncological viruses that induce TLS-like structures.
0 · Reply
Piero606
Piero606 Oct. 25 at 5:47 AM
$CADL Recent studies confirm that the presence of mature TLS correlates with better survival in solid tumors (e.g. melanoma, NSCLC, lung), and their assembly is a "bottleneck" for antitumor immunity. Positioning the TLS inductor as a "TME reprogrammer" is right: it transforms a hostile environment into a pro-inflammatory one, potentially saving that 70% of patients who do not respond to ICI. • Multimodal innovation with HSV-1 oncolytic virus: Using a programmable HSV-1 is brilliant, because it exploits the selective lysis of cancer cells to release antigens and stimulate innate immunity (via PAMPs and DAMPs). The AI touch with enLIGHTEN™ to design multi-gene payloads that recapitulate the 4-phase cascade (probably: initial recruitment, stromal organization, DC/T trigger, B/HEV maturation) exceeds the limits of single agonists such as LIGHT or LTBR.
1 · Reply
strategicmind
strategicmind Oct. 24 at 11:56 PM
$CADL let’s go! Our fearless leader
1 · Reply
ShadowBull3745
ShadowBull3745 Oct. 24 at 10:31 PM
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 24 at 10:17 PM
$CADL great turnaround … Dr PPT 😍😍
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Oct. 24 at 10:16 PM
1 · Reply
moneyboy77
moneyboy77 Oct. 24 at 10:10 PM
$CADL what are the next catalysts here. ?
1 · Reply
dirkfrank
dirkfrank Oct. 24 at 8:19 PM
0 · Reply
billymike
billymike Oct. 24 at 7:59 PM
$CADL suppression continues
0 · Reply
Musky49
Musky49 Oct. 24 at 7:53 PM
$CADL Hey Lucy….can you splain to me if it means what I think it might means? Please open and read X link below Asked how many cancer patients fail ICI’s annually in the USA TLS may be applicable to 70% of these patients per the forwarded post. (Another large market-will know more in a few weeks) https://x.com/i/grok/share/K7n0PuiLkG3RonenKM1pf8uRA
2 · Reply
billymike
billymike Oct. 24 at 7:16 PM
$CADL big vwap print
0 · Reply
billymike
billymike Oct. 24 at 7:13 PM
$CADL pharma deals happen over the weekend
0 · Reply
PhiloftheFuture
PhiloftheFuture Oct. 24 at 6:15 PM
Loaded up on my highest conviction holdings over the past week. $CRSP $RDW $CADL $CING
0 · Reply
Drcando
Drcando Oct. 24 at 5:49 PM
$CADL Another below average volume day Gonna pop one day soon an we will all be smiling 🙂 Wish I had more money Oofm till I get jobs done I'm still ok but would like another 3-10k shares before it pops
1 · Reply
The1Albatross
The1Albatross Oct. 24 at 4:45 PM
$CADL Took some so I don’t forget to start position with decent limits to fill. Start the crawl soon
0 · Reply
svertical1
svertical1 Oct. 24 at 4:43 PM
$IBRX $CADL $CRSP $NTLA $XBI Great article. Looks to me like Anktiva will become the holly grail of disease ‘combo treatments’. So even Pharma with lame treatment (Chemo, CPI’s, Radiation, etc) can improve PFS & OS! TAM=Trillions!
0 · Reply